Nuwellis Inc. (NUWE)
NASDAQ: NUWEHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NUWE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.84M
- P/E (TTM)
- 0.00
- EPS (TTM)
- $3,609.63
- Dividend yield
- None
- 52-week range
- 2.52 – 1,556.10
- Day range
- 3.27 – 3.78
- Volume / Avg
- 8.99K / 829.19K
- Beta
- —
- Shares outstanding
- 540.91K
52-week range
NUWE stock today
Shares of Nuwellis (NUWE) finished lower on Nov 20 at $3.41, a drop of 10.50% or $0.40 per share, versus the S&P 500's 3.70% decline. Trading was light, with 8.99K shares changing hands, about 1% of the average daily volume. Shares are 99.8% below their 52-week high of $1,556.10 and 35.3% above the 52-week low of $2.52, near the bottom of the past year's range.
Nuwellis trades at 0.0x its trailing twelve-month earnings per share of $3,609.63.
Summary generated from market data by MetaCap's automated system. Methodology
About Nuwellis
Company profileNuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients. The company was formerly known as CHF Solutions, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CEO
- Mr. Michael Kendrick McCormick
- Headquarters
- Eden Prairie, MN
- Employees
- 38
- Website
- nuwellis.com
Financial highlights
Full financialsIn fiscal 2025, Nuwellis generated $8.3 million in revenue, down 5.4% from fiscal 2024, its first annual decline since 2024. Nuwellis reported a net loss of $17.5 million, compared with a loss of $11.2 million a year earlier. Gross margin was 62.0% (down from 64.9%) and operating margin -134.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $8.27M | $8.74M | $8.86M | $8.54M | $7.92M |
| Growth | -5.38% | -1.40% | +3.76% | +7.85% | +6.45% |
| Net income | $-17.52M | $-11.16M | $-20.21M | $-14.53M | $-19.55M |
| EPS (diluted) | $-25.39 | $-353.30 | $-360.06 | $-83.55 | $-285.36 |
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-5.81 vs —
NUWE news
All NUWE news- Nuwellis to Host Webinar Discussing ULTRA-Peds Registry Results and Aquadex Performance in Critically Ill Pediatric PatientsGlobeNewswire
- Nuwellis, Inc. Highlights 13% YTD Revenue Growth and Cash Runway Through Q2 2027Nasdaq
- Nuwellis Reports Third Quarter 2026 Financial ResultsNasdaq
- Nuwellis (NUWE) Q3 2026 Earnings Call TranscriptNasdaq
- Nuwellis Reports Third Quarter 2026 Financial Results and Business Update Highlighted by 430 Basis Point Gross Margin Expansion and 13% Reduction in Operating Expenses, Driving 24% Improvement in Operating LossGlobeNewswire
- Nuwellis Submits FDA 510(k) to Expand Aquadex SmartFlow® Indication to Include Pediatric Patients Weighing 5 kg and AboveGlobeNewswire
- Nuwellis to Report Third Quarter 2026 Financial Results on November 12GlobeNewswire
- Nuwellis Announces Acceptance of Multicenter Pediatric Aquadex Study in Pediatric NephrologyGlobeNewswire
Nuwellis peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NXLNexalin Technology Inc. | 1.38 | -2.13% | $1.71M | vs NUWE |
| VBIOValion Bio Inc. | 0.4806 | -10.98% | $1.04M | vs NUWE |
| NDRAENDRA Life Sciences Inc. | 3.58 | -3.38% | $5.36M | vs NUWE |
| IRIXIRIDEX Corporation | 0.4449 | -4.59% | $7.92M | vs NUWE |
| ITOCiTonic Holdings Ltd Class A | 1.59 | +6.00% | $11.63M | vs NUWE |
| QTIQT Imaging Holdings Inc. | 1.92 | +2.67% | $28.21M | vs NUWE |
| ECORelectroCore Inc. | 4.42 | -8.87% | $40.78M | vs NUWE |
| POCIPrecision Optics Corporation Inc. | 4.12 | +1.41% | $45.30M | vs NUWE |
Indexes, lists and sector
Nuwellis stock FAQ
What is Nuwellis's stock price today?
NUWE last traded at $3.41 as of Nov 20, 4:00 PM EST, down 10.50% on the day. Prices are delayed at least 15 minutes.
Does Nuwellis pay a dividend?
No. Nuwellis does not currently pay a regular cash dividend.
What is NUWE's P/E ratio?
NUWE trades at a trailing P/E ratio of 0.00.
Who is Nuwellis's CEO?
Mr. Michael Kendrick McCormick is the chief executive officer of Nuwellis Inc., which has about 38 employees.
Has NUWE ever split its stock?
Yes. The most recent NUWE stock split was a 1-for-9 split on Oct 27, 2026.
What is the NUWE 52-week high?
The 52-week high for NUWE is $1,556.10 and the 52-week low is $2.52. The stock is currently 99.8% below its high.